Hope for rare wolfram syndrome: drug aims to slow diabetes progression
NCT ID NCT05676034
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests an experimental drug called AMX0035 in 12 adults with Wolfram syndrome, a rare genetic disorder that causes diabetes and vision loss. The goal is to see if the drug can help preserve the pancreas's ability to make insulin and to check its safety over up to 4 years. Participants take the drug by mouth and wear a continuous glucose monitor throughout the study.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for WOLFRAM SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Washington University
St Louis, Missouri, 63110, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a common drug slow vision loss in rare wolfram syndrome?
- Gene study aims to solve wolfram syndrome mystery
- Scientists turn skin and blood into insulin factories to fight diabetes
- Rare disease mystery: what causes fecal incontinence in wolfram syndrome?
- Global registry launches to unlock secrets of rare wolfram syndrome